These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31672485)

  • 1. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
    Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
    Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
    Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
    Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
    Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
    Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
    Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
    World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
    Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
    Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
    Thomas BM; Smith C; Evans J; Button MR; Kumar S; Palaniappan N; Staffurth J; Tanguay JS; Lester JF
    Med Oncol; 2013 Dec; 30(4):719. PubMed ID: 24026658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer.
    Caram MEV; Kumbier K; Tsao PA; Burns J; Sparks JB; Stensland KD; Reichert ZR; Alumkal JJ; Hollenbeck BK; Shahinian V; Tsodikov A; Skolarus TA
    Cancer Med; 2024 Jun; 13(12):e7334. PubMed ID: 39143030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Tseng CS; Yang JH; Huang SW; Wang YJ; Chen CH; Pu YS; Cheng JC; Huang CY
    BMC Cancer; 2023 Jun; 23(1):568. PubMed ID: 37340337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
    Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
    Carrot A; Oudard S; Colomban O; Fizazi K; Maillet D; Sartor O; Freyer G; You B
    JCO Clin Cancer Inform; 2024 Feb; 8():e2300208. PubMed ID: 38364191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
    Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.
    Robin G; Basappa NS; North S; Ghosh S; Kolinsky M
    Curr Oncol; 2024 Aug; 31(9):5080-5087. PubMed ID: 39330003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
    Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
    Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
    Sonpavde G; Huang A; Wang L; Baser O; Miao R
    BJU Int; 2018 Jun; 121(6):871-879. PubMed ID: 29388324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival.
    Maj-Hes A; Szarvas T; Sevcenco S; Kramer G
    Adv Ther; 2021 Jul; 38(7):3831-3841. PubMed ID: 34043207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.